Treatment of type 1 diabetes by islet transplantation is currently limited by loss of functional -cell mass after transplantation. We investigated here whether adenovirusmediated changes in AMP-activated protein kinase (AMPK) activity, previously shown to affect insulin secretion in vitro, might affect islet graft function in vivo. In isolated mouse and rat islets, insulin secretion stimulated by 17 (vs 3) mmol/l glucose was inhibited by 36·5% (P<0·01) and 43% (P<0·02) respectively after over-expression of constitutively-active AMPK-(AMPK CA) versus null (eGFP-expressing) viruses, and glucose oxidation was decreased by 38% (P<0·05) and 26·6% (P<0·05) respectively. Increases in apoptotic index (terminal deoxynucleotide transferase-mediated deoxyuridine trisphosphate biotin nick end-labelling) (TUNEL)) were also observed in AMPK CA-(22·8 3·6% TUNEL-positive cells, P<0·001), but not AMPK DN-(2·72 3·9%, positive cells, P=0·05) infected islets, versus null adenovirustreated islets (0·68 0·36% positive cells). Correspondingly, transplantation of islets expressing AMPK CA into streptozotocin-diabetic C57 BL/6 mice improved glycaemic control less effectively than transplantation with either null (P<0·02) or AMPK-DN-infected (P<0·01) islets. We conclude that activation of AMPK inhibits -cell function in vivo and may represent a target for therapeutic intervention during islet transplantation.
Introduction
In the wake of improvements achieved by Shapiro et al. (2000) , human islet transplantation is now considered a potentially useful treatment modality for type 1 diabetes (Korsgren et al. 2005) . At present, however, the shortage of transplantable human islet material and the requirement for multiple donors severely limit the usefulness of this approach. This problem is further aggravated by the substantial (60-80%) and time-dependent loss of islet material that appears to occur after transplantation (Korsgren et al. 2005 , Rickels et al. 2005 . A similar phenomenon is observed in other species (Davalli et al. 1995) and probably occurs by multiple, non-immune and immune-mediated mechanisms (Korsgren et al. 2005) . Strategies which inhibit these losses, and thus enhance -cell survival, are therefore likely to reduce the number of islet equivalents required initially, and to extend the usefulness of islet transplantation. To this end, adenovirusmediated introduction into islets of potentially cytoprotective genes, such as bcl-2 (Contreras et al. 2001) , insulin-like growth factor-1 (Giannoukakis et al. 2000a) , I -B kinase inhibitor (Rehman et al. 2003) , I -B repressor (Giannoukakis et al. 2000b) , erythropoietin (Fenjves et al. 2004) or a tumour necrosis factor (TNF) receptor fusion decoy (Machen et al. 2004) , is considered an exciting approach.
Adenosine monophosphate-activated protein kinase (AMPK), an evolutionarily conserved serine/threonine kinase (Carling 2004) , is ubiquitously expressed in mammalian tissues and is involved in the regulation of substrate (notably fatty acid) oxidation. AMPK is seen as a potentially interesting therapeutic target for type 2 diabetes (Ruderman & Prentki 2004) , since activation of the enzyme in muscle and liver enhances glucose uptake and suppresses glucose release respectively (Zhou et al. 2001) . Changes in AMPK activity in these tissues have thus been proposed to be involved in the anti-hyperglycaemic effects of metformin and the glitazone class of antidiabetic drugs (Fryer et al. 2002) . On the other hand, activation of AMPK in isolated rodent and human islets, as well as clonal cells, suppresses glucose metabolism and glucosestimulated insulin secretion (GSIS) (da Silva Xavier et al. 2000 , Eto et al. 2002 , and enhances -cell death through apoptosis (Kefas et al. 2003b) (F Diraison and G A R, unpublished data) . Importantly, the extent to which AMPK activation in the cell limits the otherwise beneficial effects of the above antihyperglycaemic agents is presently unexplored .
The role of AMPK in the regulation of insulin secretion is largely untested in vivo. Thus, while whole-body inactivation of the 2-isoform of the catalytic subunit by homologous recombination in mice (Viollet et al. 2003) leads to abnormal glucose tolerance, this appears largely to be the result of increased sympathetic tone. Importantly, islets isolated from 2-knockout mice display no evident abnormalities in glucose-stimulated insulin secretion ex vivo (Viollet et al. 2003) , consistent with the predominant expression of 1 in islets and cells (da Silva Xavier et al. 2000) . Moreover, compensatory increases in AMPK 1 activity in cells cannot be ruled out in the 2 knockout mouse model.
The present study was undertaken with two aims in mind:
1. to clarify the role of AMPK in the control of insulin secretion and -cell mass in vivo 2. to assess the therapeutic potential of islet-specific regulation of the enzyme in a rodent model.
We demonstrate that adenovirus-mediated overexpression of an activated form of AMPK (Woods et al. 2000) markedly inhibits the improvement of glycaemic control achieved by transplantation of islets under the kidney capsule of streptozotocin-diabetic syngeneic mice, demonstrating the potential importance of AMPK in controlling functional -cell mass in vivo.
Materials and Methods

Adenoviral preparation
Adenoviruses expressing the constitutively active NH 2 -terminal fragment common to mammalian AMPK 1 and 2 (AMPK1-312,T 172 D; Ad-AMPK CA), and the fulllength AMPK 2 mutated in the active site (D 157 A; Ad-AMPK DN) or enhanced green fluorescent protein alone (Ad-eGFP) were generated as described by subcloning the corresponding cDNAs into pAdTrackCMV (He et al. 1998) . Viruses were amplified in HEK293 cells and purified as described on CsCl gradients (Ainscow & Rutter 2001) .
Animals
Inbred male C57 BL/6 mice aged 8-14 weeks (20-25 g) were used as donors and transplant recipients. All experimental mice were bred and housed in the specificpathogen-free facility, University of Bristol. They were housed at 22 C with 12-h light/dark cycle and ad libitum access to chow and water. Procedures were performed in accordance with UK Home Office regulations, and the NIH 'Principles of Laboratory Animal Care' were followed throughout. Male Wistar rats (220-250 g) were supplied by the University of Bristol Medical School Animal Facility.
Islet isolation
Donor mice were killed by cervical dislocation and underwent laparotomy to expose the common bile duct. The duct was then clamped at its insertion into the duodenum and cannulated proximally with a 27-gauge needle and 3 ml collagenase P solution (1 mg/ml, Sigma) in Hanks' buffered salt solution (HBSS; Gibco) supplemented with 0·01 M HEPES, pH 7·4) injected. Isolated pancreata were digested at 37 C for 8-9 min. After incubation, the digested tissue was washed, hand-shaken and centrifuged at 170 g for 3 min with HEPES-buffered HBSS (see above) augmented with 5% fetal calf serum (FCS). After passing through a 1 mm tissue-collecting sieve, islets were purified on a discontinuous Ficoll density gradient (Sigma) (Gotoh et al. 1985) . Islets were handpicked and transferred into Dulbecco's modified Eagle's medium (DMEM) (Sigma) supplemented with 10% FCS, 11 mM glucose, 100 i.u./ml penicillin and 100 µg/ml streptomycin for further culture.
Ex vivo gene transfer into mouse islets
Islets were infected with Ad-eGFP, Ad-AMPK CA or Ad-AMPK DN at a multiplicity of infection (MOI) of 50-100 plaque-forming units per islet cell (assuming islets contained an average of 2000 cells) (Flotte et al. 2001 ) for 16 h. Infection of islets with the null virus at this MOI did not provoke any changes in apoptotic index or glucose-stimulated insulin secretion in comparison to uninfected islets (results herein) . Islets were then incubated for 48 h at 37 C in 5% CO 2 prior to ex vivo studies, or were transplanted immediately.
Extraction and assay of AMPK activity
For uniformity, mass islet isolations were performed and the resulting islets divided into aliquots for viral infection and comparison. Equal numbers and sized islets were infected with one of each of the three constructs (AdeGFP, AdAMPK-CA or AdAMPK-DN). Quantification of AMPK activity was performed as described previously . In brief, 400 transduced islets were scraped into ice-cold lysis buffer (50 mM Tris-HCl, pH 7·4, at 4 C/250 mM sucrose/50 mM NaF/1 mM sodium pyrophosphate/1 mM EDTA/1 mM EGTA/ 1 mM DTT/1% (v/v) Triton X-100/complete protease inhibitor mixture; Roche Diagnostics). Extracts were centrifuged (13 000 g for 5 min at 4 C), and protein concentration was determined with DC protein assay reagent (Bio-Rad). This protocol releases over 90% of total cellular content of each AMPK isoform (Salt et al. 1998) . AMPK was immunoprecipitated from 100 µl cell extract with either sheep anti-1 or anti-2 antibodies. AMPK activity was measured in 10 µl crude extract by using 'SAMS' peptide (the synthetic peptide HMRSAMSGLHLVKRR) and -32 P-ATP (specific activity, 1000 c.p.m./pmol).
Insulin secretion
At 48 h after adenoviral infection, islets were incubated for 60 min at 37 C in 2 ml Krebs-Ringer bicarbonate HEPES buffer (KRBH) (130 mM NaCl, 3·6 mM KCl, 1·5 mM CaCl 2 , 0·5 mM MgSO 4 , 0·5 mM KH 2 PO 4 , 2·0 mM NaHCO 3 and 10 mM HEPES) supplemented with 3 mM glucose and 0·5% (w/v) BSA pre-equilibrated with 95% O 2 :5% CO 2 , pH 7·4. Islets were separated into three groups of five islets per condition and incubated for 30 min in 1 ml KRBH as above containing either 3 or 17 mM glucose. Total insulin was extracted in acidified ethanol (75% EtOH, 23·5% H 2 O and 1·5% HCl). Insulin was measured by radioimmunoassay by competition with 125 I-labelled rat insulin (Linco Research, St Charles, MO, USA) according to the manufacturer's instructions. Released insulin is expressed as percentage of the total cellular (extractable) insulin content.
[U-14 C]Glucose oxidation
Islets were preincubated for 30 min at 37 C in KRBH supplemented with 3 mM glucose and 0·5% BSA (w/v). Triplicate groups of 100 islets were then placed in 250 µl KRHB containing 3 or 17 mM unlabelled glucose, 1·7 µCi [U-
14
C]glucose and 0·5% BSA (w/v) in a 24-well plate. A rubber gasket, the size of the 24-well plate and containing 0·5 cm holes, was aligned over the plate. A CO 2 capture chamber was created as described previously (Collins et al. 1998) . A UniFilter-24 GF/B plate (Packard Instrument, Research Parkway Meridien, Connecticut, USA) was sealed with an adhesive sheet, and 100 µl of 40% (w/v) KOH were pipetted onto each filter. The filter plate was inverted and aligned over the rubber gasket to form a small CO 2 capture chamber. Finally, the chamber was sealed with a 6 mm glass plate, a 6 mm metal plate and a lead weight to ensure an airtight seal. The apparatus was incubated for 2 h at 37 C. Filters were removed, and captured 14 CO 2 was measured by scintillation counting. Control incubations lacking islets were included in each incubation series.
Preparation of islet cryostat sections and immunocytochemistry
Islets were infected with adenoviruses, cultured for 48 h and then washed with PBS and fixed with 3% (w/v) formaldehyde for 16 h at 4 C. For sectioning, islets were fixed with Zamboni's fixative (Stefanini et al. 1967) overnight at 4 C, immersed in a solution of 30% (w/v) sucrose in PBS overnight, and subsequently frozen in OCT compound (Tissue-Tek; Sakura Finetecnical, Tokyo, Japan). Islet sections (10 µm) were obtained with a cryostat (Bright OTF5000, Jencons, Leighton Buzzard, UK). Islet slices were permeabilized with 0·3% (w/v) Triton X-100 overnight, and then blocked in 3% (w/v) BSA in PBS for 15 min. Slices were incubated with guinea pig anti-insulin antiserum at 1:500 dilution in a humidified chamber at 4 C overnight. After washing with PBS, islets were incubated again overnight at 4 C with tetramethyl rhodamine isothiocyanate (TRITC)-conjugated anti-guinea pig antibody (1:500 dilution). After a final wash in PBS, islet slices were mounted in a mixture of Mowiol (Merck) and glycerol. Images were captured on a Leica SP2 laser scanning confocal microscope with a 63 oil immersion objective with excitation at 350, 488 (Ar) and 543 nm (He-Ne) . Emitted light was detected at >515 nm for eGFP (green) or >560 nm for insulin (red).
Terminal deoxynucleotide transferase-mediated deoxyuridine trisphosphate nick end-labelling (TUNEL) assay
Islets were cultured for 72 h with null, AMPK CA or DN adenoviruses at 100 MOI as indicated. Islets were then washed twice with ice-cold PBS and 10 µm cryostat sections prepared as above for immunocytochemistry. Sections were permeabilized in 0·2% (v/v) triton X-100 in PBS for 1 h at 4 C before incubation with TUNELlabelling solution containing terminal deoxynucleotidyl transfersase (Roche) for 1 h at 37 C. Slides were then washed twice with PBS and incubated in DAPI (Sigma; 10 µg/ml) in PBS for 10 min. After a final wash in PBS, sections were mounted in movial solution. Positive controls to test the specificity of the TUNEL assay were prepared by incubating in DNase 1 (Roche; 100 U/ml) in 50 mM Tris-HCl, pH 7·5, 1 mg/ml BSA for 10 min at room temperature. Islets were imaged on an SP2 Leica confocal microscope with excitation at 560 nm for TMRred-labelled nucleotides (red), 488 nm for eGFP (green) and 350 nm for DAPI nuclear staining, and the number of apoptotic cells was counted. The number of TUNELpositive (apoptotic) cells was counted and expressed as a percentage of total number of cells per islet. At least 12 islets were counted in each case.
Preparation of islets for transplantation
After three gentle washes, transduced islets were handpicked and carefully counted. Islets were placed into a 1·5 ml tube on ice and pelleted by centrifugation. Supernatant was removed and the islet pellet transferred into a sterile P200 pipette tip plugged with wax. The pipette tip was centrifuged at 170 g for 3 min, and the supernatant was aspirated to yield a dry islet pellet at its tip.
Islet transplantation
To induce diabetes, animals were fasted overnight and then administered 160 mg/kg of streptozotocin (STZ) (Sigma) in citrate buffer (0·1 M sodium citrate and 0·1 M citric acid, pH 4·5) by an intraperitoneal route. Transplantation was carried out 3 days after administration of STZ. Blood glucose levels were determined by an Accucheck II blood glucose monitor (Roche) using whole blood collected from the tail vein. Mice with a blood glucose value over 20 mmol/l were used as transplant recipients. Mice were anaesthetized by an intraperitoneal injection of fentanyl (10 mg/ml; Hypnorm, Janssen, Wantage, UK) and midazolam (5 mg/ml; Hypnovel) mixed with sterile distilled water in a ratio of 1:1:2, and a volume of 50-100 µl was administered. The left kidney was accessed through a small subcostal incision. A small puncture was made in the renal subcapsule over the inferior pole, and the pipette tip containing the islets was inserted under the capsule and advanced to the superior pole. The islet pellet was then deposited and the pipette tip carefully removed without spillage. The kidney was replaced in the peritoneal cavity and the skin stapled with clips (SLS, Nottingham, UK).
Blood glucose analysis was performed on postoperative day (POD) 1 and thrice weekly to 30 days and thereafter weekly to day 100. In accordance with UK Home Office regulations, animals losing over 15% of preoperative body weight or in distress were killed.
Intraperitoneal glucose tolerance tests
An intraperitoneal glucose tolerance test (IPGTT) was performed on surviving recipients at POD 30. The animals were fasted overnight for not more than 16 h. Each animal was then weighed, and a starved blood glucose value recorded. Animals were fasted overnight, and after administration of a 10% intraperitoneal glucose solution (2 g/kg body mass), samples of blood were taken from the tail vein at 15, 30, 60 and 120 min after the glucose challenge.
Graft nephrectomy
Animals were anaesthetized and the old incision was opened. The left kidney containing the graft was carefully dissected away from peritoneum and adhesions. The renal pedicle was identified and suture ligated with 4/0 vicryl (Ethicon, Edinburgh, UK). The kidney was then excised and the skin closed once more with clips. Blood glucose analysis was performed at 1 and 24 h after graft nephrectomy.
Statistics
Data are given as means S.E.M. Comparisons between means were performed with Student's t-test for unpaired data, or one-way ANOVA with post hoc Bonferroni correction for measurements of glycaemia, using Graphpad Prism (GraphPad Software Inc., San Diego, CA, USA).
Results
Effects of changes in AMPK activity on glucose metabolism, insulin secretion and apoptosis in isolated mouse islets
Infection of islets with Ad-eGFP, Ad-AMPK CA or Ad-AMPK DN (see Materials and Methods) was confirmed by confocal microscopy to detect eGFP fluorescence. Similar levels of eGFP expression were apparent after infection with each virus (Fig. 1A) . The efficiency of infection ranged from 25% in the majority of islets (>150 µm) to 70% in smaller islets (diameter of <100 µm), with a predominant localization in peripheral, insulin-positive cells as observed previously in rat islets (Fig. 1A) . Transduction with AMPK-expressing viruses was associated with the expected changes in extractable AMPK activity (Fig. 1B) .
Over-expression of AMPK CA in isolated mouse islets inhibited glucose-stimulated insulin secretion (17 versus 3 mM) by approximately 40% (P<0·01), but there was no marked effect after expression of dominant-negative AMPK (AMPK DN). Similar findings were observed in rat pancreatic islets where AMPK CA inhibited the secretion of insulin in response to glucose by 50% (P<0·01) (results not shown) as consistent with previous results (Diraison et al. 2003 . No effect of either virus (CA or DN) on total islet insulin content was observed after infection of islets from either species (data not shown).
We next determined whether the effects of overexpression of AMPK CA may be explained in part by a reduction in glucose oxidation, given the previous finding of a decrease in glucose-induced changes in -cell ATP content and reduced pyridine nucleotide fluorescence . In control mouse islets expressing eGFP alone (Null virus-infected), a five-fold induction in the oxidation of [U-14 C]glucose was observed at elevated (17 versus 3·0 mM) glucose concentrations (Fig. 2) . This increase was significantly (30%, P<0·05) inhibited in mouse islets that over-expressed AMPK CA. In contrast, islets transduced with AMPK DN showed no significant difference in the oxidation of glucose at either glucose concentration. Essentially similar data were obtained with rat islets (data not shown).
Previous reports have suggested that pharmacological activation of AMPK, or expression of the constitutively activated enzyme in -cell lines (Kefas et al. 2003a,b) and purified rat cells (Kefas et al. 2003b (Kefas et al. , 2004 , can lead to apoptosis. To determine whether over-expression of activated AMPK may induce apoptosis in cells in the context of the intact, isolated mouse islet, we monitored DNA cleavage in islet slices by incorporating tetramethyl rhodamine-labelled nucleotides into the free 3 -OH end of DNA strand breaks, using terminal deoxynucleotidyl transferase (TUNEL assay). The number of apoptotic cells was then counted in islets infected with null (eGFP), Ad-AMPK CA or Ad-AMPK DN viruses. Whereas expression of AMPK DN had no significant effect on the number of apoptotic cells compared with null virus, AMPK CA caused a 30-fold increase after 72 h of infection (Table 1) .
Impact of changes in islet graft AMPK activity on glycaemic control
We next explored the cytoprotective and metabolic effects of modulating -cell AMPK activity in vivo by monitoring the survival and function of a suboptimal islet mass transplanted into syngeneic diabetic mice. To this end, a suboptimal islet transplant mass was first determined. Islets were treated with adenoviruses in culture for 16 h before transplantation. This period was chosen to ensure adequate uptake of viral particles by the islet, while avoiding the deleterious effects (e.g. central islet necrosis or changes in islet vasculature) of extended islet culture in vitro. Indeed, we observed no recovery of glycaemia after transplantation with islets previously cultured for 48 h, even at high islet numbers (600 islets/animal; n=8). We defined a suboptimal mass as the number of adenovirally infected transplanted islets that would have less than a 25% success rate in restoring euglycaemia (defined as two consecutive post-transplant blood glucose readings below 15 mmol/l). Preliminary data showed that transplantation of 600 islets resulted in a cure rate of 100% (n=5), while 
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transplantation of 300 islets resulted in a cure rate of 25% (n=4). To confirm that the transplantation of 300 islets constituted a suboptimal islet mass, diabetic mice were transplanted with 200 islets, resulting in no improvement in glycaemia compared with untransplanted animals (n=6). These experiments (see Figure 7) established that transplantation of 300 islets constituted a suboptimal, marginal islet mass, likely to be most sensitive to any effect of increasing or decreasing AMPK activity. To test whether AMPK manipulation could affect -cell function during the early post-transplantation period, 300 Ad-AMPK CA-or Ad-AMPK DN-infected islets were transplanted into diabetic mice, and blood glucose levels were monitored over a 20-day period. Mice transplanted with 300 Ad-eGFP-infected islets were used as controls. Comparing the mean blood glucose value for mice receiving 300 Ad-AMPK CA islets (n=8) to those mice receiving Ad-eGFP(control) virus-infected islets (n=8) over the 20-day period showed significant impairment in glycaemic control in the Ad-AMPK CA group (P=0·0016; Fig. 3A ). By contrast, the mean blood glucose levels for mice receiving Ad-AMPK DN (n=7) islets were not significantly different from those observed in mice receiving Ad-eGFP (control) virus-infected islets (n=8) (P=0·64) (Fig. 3B) . However, when mice transplanted with Ad-AMPK CA-infected islets (n=8) and Ad-AMPK DN-infected islets (n=7) (Fig. 3C) were compared, a significant impairment in glycaemic control was seen in the former cohort (P=0·009).
Mice were weighed and monitored regularly over a 30-day postoperative period. All mice transplanted with Ad-eGFP-transduced islets survived this period (n=8). Of the mice receiving Ad-AMPK-CA-or Ad-AMPK-DN-infected islets, 6/8 (75%) and 6/7 (86%) survived respectively. The cohorts' 30-day weight change is shown in Fig. 4 . The mean weight change in surviving mice receiving Ad-AMPK CA-infected islets was significantly less than in those mice receiving Ad-AMPK DN-infected islets (-9·0 4·4% vs 3·25 3·25%; P=0·03). There was no significant difference when comparing surviving mice transplanted with Ad-eGFP (control) islets (1·31 4·1%) and either Ad-AMPK CA islets (P=0·06) or Ad-AMPK DN-infected islets (P=0·36).
For a finer assessment of the function of the transplanted islets in vivo, an intraperitoneal glucose tolerance test (IPGTT) was performed. The model was established with control non-diabetic mice and STZ-induced diabetic mice without islet transplantation (Fig. 5A) . Each contemporaneous cohort of mice underwent IPGTT on POD 30 (Fig. 5A) . The mean area under the curve (AUC) in surviving mice receiving Ad-AMPK CA-infected islets (2947 178·6, n=6) was significantly greater than in animals receiving Ad-eGFP-infected islets (2341 183·3, n=8, P<0·04) or Ad-AMPK DN-infected islets (1971 243·8, n=6, P=0·01) , demonstrating poorer glucose tolerance (Fig. 5B) . To verify that the changes reported above reflected differences in graft function rather than recovery of endogenous -cell mass, nephrectomy was performed on a single cohort of three previously transplanted animals, 100 days after the original transplantation. Each animal showed an elevation in blood glucose concentration within 1 h, and at 24 h all were hyperglycaemic (>20 mmol/l) (Fig. 6 ).
Discussion
Effects of AMP-activated protein kinase on glucose-stimulated insulin secretion in vitro
Over-expression of activated AMPK in intact mouse islets is shown here markedly to suppress glucose oxidation, 
Figure 7
Transplantation of 300 islets represents a suboptimal islet mass. Diabetic mice were transplanted with 600 (n=5), 400 (n=7), 300 (n=4) or 200 (n=6) isolated islets that had been incubated for 16 h. All mice transplanted with 600 islets were euglycaemic by POD 3 (blood glucose of<15 mmol/l). Forty-three per cent and 25% of animals transplanted with 400 and 300 islets respectively were euglycaemic by POD 3. None of the animals transplanted with 200 islets achieved euglycaemia over the same time period.
consistent with previous measurements of ATP content and reduced pyridine nucleotide fluorescence in rat islets and clonal -cells (da Silva Xavier et al. 2000 . Similarly, glucose-stimulated insulin secretion was inhibited to a similar extent by over-expression of AMPK CA, suggesting that changes in glucose metabolism may be the principal mechanism through which AMPK activation affects glucose-stimulated insulin secretion. Interestingly, these changes were observed despite the relatively low infection efficiency (20-30%) with the virus, an observation which probably reflects the fact that the outermost layers of cells are the most active metabolically and in terms of glucose-stimulated insulin release after a period of culture, where degradation of the intraislet vasculature is likely. These levels of infection were not significantly increased in medium-large islets (over 150 µm diameter) even up to an MOI of 1000 in our hands, a point at which apoptosis becomes apparent after expression of null (Ad-eGFP) virus (L Parton, F Diraison and G A R, unpublished results; see also Diraison et al. 2004) .
Expression of AMPK CA also led to a dramatic increase in islet cell apoptosis in vitro, a phenomenon which seems likely to contribute substantially to the increased incidence of islet failure after islet transplantation in vivo. These observations are consistent with very recent findings showing that activation of AMPK leads to cell-cycle arrest in a number of cell types (Nagata et al. 2004 , Xiang et al. 2004 , Jones et al. 2005 , and with the identification of the tumour suppressor LKB1 as an important upstream AMPK kinase (Hawley et al. 2003 , Woods et al. 2003 . Whether apoptosis in cells is the cause or the consequence of altered glucose metabolism remains to be firmly established, but the fact that treatment of islet or cells with 5-amino-imidazole carboxamide riboside (AICAR) or the AMPK-activator metformin ) rapidly inhibits insulin release suggests that apoptosis may be a downstream consequence of the metabolic changes (Kefas et al. 2004) .
By contrast, introduction of AMPK DN was largely without effect on glucose oxidation or insulin release. The latter finding in mouse islets differs from our previous results obtained in rat (da Silva Xavier et al. 2000) or human islets, where introduction of AMPK DN caused an increase in insulin release at submaximal glucose concentrations. It should be emphasized, however, that no effort was made in the present study to investigate the effects of AMPK selectively on smaller islets, where higher efficiencies of transfection (>70%) were achieved in our earlier studies .
Effects of AMPK activation on islet function in vivo
The findings described here extend to the in vivo setting the results of the present and previous (da Silva Xavier et al. 2000 ) studies using isolated islets. The decrease in apparent -cell function observed after the transplantation of islets expressing AMPK CA presumably reflects both the poorer acute response to glucose, and a decrease in -cell mass due to enhanced apoptosis (see above) (Kefas et al. 2003b) .
A loss of functional -cell mass of up to 70% occurs after transplantation in man (2). In the present work, activation of AMPK is shown to be detrimental to -cell function and survival in vivo. However, despite a tendency to improved glucose tolerance compared with null virus treatment (Fig. 4A ), we were unable to affect islet function significantly after transplantation by expression in islets of a dominant-negative form of AMPK. There may be two possible explanations for this observation. Firstly, endogenous AMPK may remain essentially unstimulated in transplanted islets, at least at early time points. Secondly, the relatively small (15%; Fig. 1B ) decrease in AMPK activity observed in vitro seems likely to be due to changes in cells situated at the islet periphery which were efficiently transduced with the virus, leaving cells deeper within the islet core unaffected.
In conclusion, we demonstrate that expression of activated AMPK selectively in pancreatic islets affects glucose metabolism, insulin secretion and -cell survival, and is associated with decreased -cell function in vivo. We propose that suppression of islet AMPK activity may thus represent a potential therapeutic target for intervention after islet transplantation in type 1 diabetics.
